에 대한 최신 뉴스 Global Medical REIT (NYSE:GMRE) 주식

Global Medical REIT

Global Medical REIT Inc is a Maryland corporation engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.

Global Medical REIT Inc

Global Medical REIT Inc. Series A Cumulative Redeemable Preferred Stock

<p><i><strong>Chief Executive Officer Transition Expected in 2025</strong></i></p>
<p><i><strong>Mr. Busch to Remain on Board of Directors as Non-Executive Chairman</strong></i></p>
<p><i><strong>Lori Wittman Appointed Lead Independent Director Effective January 1, 2025</strong></i></p>
<p>Global Medical REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) (the "Company" or "GMRE"), a net-lease medical real estate investment trust (REIT) that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced that as part of the Company's succession planning efforts, the Board of Directors (the "Board") has reached an agreement with Mr. Jeffrey Busch, Chairman of the Board of Directors and Chief Executive Officer ("CEO") of the Company, regarding Mr. Busch's transition from service as CEO and with anticipated continuation as a member of the Board.</p>
<p>Pursuant to the agreement with Mr. Busch, his service as CEO will end on the first to occur of (i) the date that a successor CEO has been appointed by the Board pursuant to the Company's CEO succession plan or (ii) June 30, 2025 (such date that is first to occur, the "Succession Date").</p>


News

Management

GMRE

Global Medical REIT Announces Succession Plan; CEO Transition Expected In 2025; Jeffrey Busch To Remain On Board Of Directors As Non-Executive Chairman; Lori Wittman Appointed Lead Independent Director Effective January 1, 2025

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year.  The company reported quarterly sales of $34.175 million which missed the analyst consensus estimate of $34.645 million by 1.36 percent.  This is a 3.70 percent decrease over sales of $35.487 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Global Medical REIT Q3 2024 FFO $0.22 Beats $0.20 Estimate, Sales $34.175M Miss $34.645M Estimate

<p>Berenberg  analyst Kai Klose   initiates coverage on Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy rating and announces Price Target of $11.75.</p>


Price Target

Initiation

Analyst Ratings

Berenberg Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $11.75

<p>Alliance Global Partners   initiates coverage on Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy rating and announces Price Target of $12.</p>


Alliance Global Partners Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $12

<p>B. Riley Securities  analyst Bryan Maher   maintains Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy and lowers the price target from $11 to $10.</p>


B. Riley Securities Maintains Buy on Global Medical REIT, Lowers Price Target to $10

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.21 by 9.52 percent. This is unchanged from the same period last year.  The company reported quarterly sales of $35.069 million which beat the analyst consensus estimate of $33.938 million by 3.33 percent.  This is a 3.12 percent decrease over sales of $36.199 million the same period last year.</p>


Global Medical REIT Q1 2024 FFO $0.23 Beats $0.21 Estimate, Sales $35.069M Beat $33.938M Estimate

<p>Wednesday marks the last chance for investors to receive the next  dividend payout from <strong>Global Medical REIT</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>). </p>
<h3>What's Happening</h3>
<p>The company announced on Thursday that it would pay shareholders a quarterly dividend of 21 cents per share. On Thursday, Global Medical REIT will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 21 cents lower than it would have opened on any other day.</p>
<p>In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Thursday. Shareholders who own GMRE as of the end of Wednesday's session are eligible to receive the 21 cents dividend payout for every share that they own. </p>
<p>According to the company, this dividend will be paid out to shareholders on April 09, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. </p>
<p>To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar. </p>


Dividends

Global Medical REIT: Dividend Insights

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent.  The company reported quarterly sales of $32.93 million which missed the analyst consensus estimate of $35.64 million by 7.60 percent.  This is a 9.26 percent decrease over sales of $36.29 million the same period last year.</p>


Global Medical REIT Q4 2023 FFO $0.23 Beats $0.22 Estimate, Sales $32.93M Miss $35.64M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

<p>By the end of today, January 09, 2024, <b>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>)</b> is set to deliver a dividend payout of $0.21 per share, equating to an annualized dividend yield of 8.06%. The company's dividend payout went ex-dividend on December 26, 2023, so only the investors that owned the stock prior to the ex-dividend date will receive this payout. </p>
<h3>Global Medical REIT Recent Dividend Payouts</h3>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><table>
<thead>
<tr>
<th><strong>Ex-Date</strong></th>
<th style="text-align: right;"><strong>Payments per year</strong></th>
<th><strong>Dividend</strong></th>
<th><strong>Yield</strong></th>
<th><strong>Announced</strong></th>
<th><strong>Record</strong></th>
<th><strong>Payable</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2023-12-26</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>8.06%</td>
<td>2023-12-12</td>
<td>2023-12-27</td>
<td>2024-01-09</td>
</tr>
<tr>
<td>2023-09-21</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>8.91%</td>
<td>2023-09-08</td>
<td>2023-09-22</td>
<td>2023-10-10</td>
</tr>
<tr>
<td>2023-06-22</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>9.08%</td>
<td>2023-06-09</td>
<td>2023-06-23</td>
<td>2023-07-11</td>
</tr>
<tr>
<td>2023-03-23</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>8.7%</td>
<td>2023-03-10</td>
<td>2023-03-24</td>
<td>2023-04-11</td>
</tr>
<tr>
<td>2022-12-21</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>8.55%</td>
<td>2022-12-07</td>
<td>2022-12-22</td>
<td>2023-01-09</td>
</tr>
<tr>
<td>2022-09-22</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>7.8%</td>
<td>2022-09-09</td>
<td>2022-09-23</td>
<td>2022-10-11</td>
</tr>
<tr>
<td>2022-06-23</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>6.7%</td>
<td>2022-06-10</td>
<td>2022-06-24</td>
<td>2022-07-08</td>
</tr>
<tr>
<td>2022-03-24</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>5.41%</td>
<td>2022-03-11</td>
<td>2022-03-25</td>
<td>2022-04-08</td>
</tr>
<tr>
<td>2021-12-23</td>
<td style="text-align: right;">4</td>
<td>$0.2</td>
<td>4.9%</td>
<td>2021-12-10</td>
<td>2021-12-27</td>
<td>2022-01-10</td>
</tr>
<tr>
<td>2021-09-23</td>
<td style="text-align: right;">4</td>
<td>$0.2</td>
<td>5.24%</td>
<td>2021-09-10</td>
<td>2021-09-24</td>
<td>2021-10-08</td>
</tr>
<tr>
<td>2021-06-23</td>
<td style="text-align: right;">4</td>
<td>$0.2</td>
<td>5.2%</td>
<td>2021-06-10</td>
<td>2021-06-24</td>
<td>2021-07-08</td>
</tr>
<tr>
<td>2021-03-23</td>
<td style="text-align: right;">4</td>
<td>$0.2</td>
<td>6.07%</td>
<td>2021-03-02</td>
<td>2021-03-24</td>
<td>2021-04-08</td>
</tr>
</tbody>
</table>
<p>Global Medical REIT's dividend yield falls in the middle range when compared to its industry peers, with <b>Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>)</b> having the highest annualized dividend yield at 25.96%.</p>
<h3>Analyzing Global Medical REIT Financial Health</h3>
<p>Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. </p>
<h3>YoY Growth in Dividend Per Share</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1704812704_0.png" alt="dividend chart graph" /></p>
<p>The company demonstrated a positive dividend growth pattern from 2020 to 2023, with the dividend per share rising from $0.80 to $0.84. This signifies the company's commitment to consistently increasing shareholder dividends.</p>
<h3>YoY Earnings Growth For Global Medical REIT</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1704812705_1.png" alt="earning chart graph" /></p>
<p>Investors can observe a growth in earnings for Global Medical REIT from 2020 to 2023, as earnings per share increased from $0.83 to $0.93. This upward trajectory in earnings indicates potential for future cash dividend payout increases, which can be advantageous for income-seeking investors.</p>
<h3>Recap</h3>
<p>This article delves into the recent dividend payout of Global Medical REIT and its implications for shareholders. Presently, the company is distributing a dividend of $0.21 per share, leading to an annualized dividend yield of 8.06%.</p>
<p>Global Medical REIT's dividend yield falls in the middle range when compared to its industry peers, with Medical Properties Trust having the highest annualized dividend yield at 25.96%.</p>
<p>The increase in both dividend per share and earnings per share from 2020 to 2023 for Global Medical REIT indicates a positive financial trend, suggesting their capacity to continue distributing profits to shareholders.</p>
<p>Keeping a close watch on the company's performance in the coming quarters will enable investors to stay abreast of any modifications in financials or dividend disbursements.</p>
<p>[Track real-time stock fluctuations for Global Medical REIT on Benzinga.](https://www.benzinga.com/quote/<b>Global Medical REIT (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gmre#NYSE">GMRE</a>)</b>)</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Small Cap

Achieving Growth and Investor Rewards: Global Medical REIT Flourishes with Strong Performance and Rising Profits

Offerings

Global Medical REIT Inc Files For Mixed Shelf Offering, Size Not Disclosed - Sec Filing

<p>Monday marks the last chance for investors to receive the next  dividend payout from <strong>Global Medical REIT</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>). </p>
<h3>What's Happening</h3>
<p>The company announced on Tuesday that it would pay shareholders a quarterly dividend of 21 cents per share. On Tuesday, Global Medical REIT will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 21 cents lower than it would have opened on any other day.</p>
<p>In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Tuesday. Shareholders who own GMRE as of the end of Monday's session are eligible to receive the 21 cents dividend payout for every share that they own. </p>
<p>According to the company, this dividend will be paid out to shareholders on January 09, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. </p>
<p><a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Global Medical REIT's previous dividends.</p>
<p>To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.  </p>


Monday Is Your Last Chance To Buy Global Medical REIT Before The Dividend Payout

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share. This is a 8 percent decrease over earnings of $0.25 per share from the same period last year.  The company reported quarterly sales of $35.49 million which missed the analyst consensus estimate of $36.00 million by 1.43 percent.  This is a 0.40 percent increase over sales of $35.35 million the same period last year.</p>


Global Medical REIT Q3 2023 AFFO $0.23 Down From $0.25 YoY, Sales $35.49M Miss $36.00M Estimate

AAON

ACVA

ADEA

ADTN

ALTO

AMPY

AMRC

AOSL

AQST

ATIP

ATSG

AUGX

AXSM

AZPN

BNTX

BWMN

CCCS

CHRS

CLLS

CLOV

COHR

CRGY

CRNT

CTRA

DCGO

DISH

DMRC

EOSE

Embraer-Empresa Brasileira De Aeronautica

EVCM

EVER

FANG

FENC

FGEN

FRPT

GATO

GOOD

GORO

HALO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HNRG

ICHR

INTR

ISPO

ITUB

JELD

KIDS

KLXE

KRYS

LINC

MGNX

MLAB

MTTR

Earnings Scheduled For November 6, 2023

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share. This is a 8 percent decrease over earnings of $0.25 per share from the same period last year.  The company reported quarterly sales of $36.32 million which beat the analyst consensus estimate of $36.29 million by 0.07 percent.  This is a 7.83 percent increase over sales of $33.68 million the same period last year.</p>


Global Medical REIT Q2 EPS $0.23 Down From $0.25 YoY, Sales $36.32M Beat $36.29M Estimate

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments"><em> high dividend payout. </em></a></p>
<p>Benzinga readers can review the latest analyst takes on&nbsp;their favorite stocks&nbsp;by visiting our&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank">Analyst Stock Ratings&nbsp;</a>page. Traders can sort through Benzinga&#39;s extensive database of analyst ratings, including&nbsp;by analyst accuracy. Here&#39;s a look at the most recent high-yield dividend&nbsp;stock ratings from the most accurate Wall Street analysts, according to Benzinga&#39;s&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock&nbsp;</a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Ratings</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3><strong>Global Medical REIT Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gmre#NYSE">GMRE</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 8.48%</li>
<li><strong>B. Riley Securities</strong> analyst Bryan Maher maintained a Buy rating and cut the price target from $12 to $11 on May 8, 2023. This analyst has an accuracy rate of 66%.</li>
<li><strong>BMO Capital</strong> analyst John Kim downgraded the stock from Outperform to Market Perform and cut the price target from $13 to $9 on Oct. 6, 2022. This analyst has an accuracy rate of 67%.</li>
<li><strong>Recent News:</strong> Global Medical REIT posted downbeat first-quarter sales.</li>
</ul>
<h3><strong>Broadstone Net Lease, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bnl#NYSE">BNL</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.87%</li>
<li><strong>Morgan Stanley</strong> analyst Ronald Kamdem maintained an Equal-Weight rating and cut the price target from $20 to $19 on Dec. 16, 2022. This analyst has an accuracy rate of 61%.</li>
<li><strong>BTIG</strong> analyst Michael Gorman maintained a Buy rating and raised the price target from $25 to $22 on Oct. 6, 2022. This analyst has an accuracy rate of 64%.</li>
<li><strong>Recent News:</strong> Broadstone Net Lease posted better-than-expected first-quarter sales.</li>
</ul>
<h3><strong>Physicians Realty Trust </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/doc#NYSE">DOC</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.24%</li>
<li><strong>Credit Suisse</strong> analyst Omotayo Okusanya reiterated a Neutral rating with a price target of $15 on March 29, 2023. This analyst has an accuracy rate of 61%.</li>
<li><strong>Keybanc</strong> analyst Todd Thomas upgraded the stock from Sector Weight to Overweight with a price target of $17 on Dec. 14, 2022. This analyst has an accuracy rate of 63%.</li>
<li><strong>Recent News:</strong> Physicians Realty Trust reported first-quarter revenue increase of 3.0% Y/Y to $134.3 million, exceeding the consensus of $132.2 million.</li>
</ul>
<p>&nbsp;</p>
<p>Read More: <a href="https://www.benzinga.com/news/earnings/23/08/33484770/markets-remain-bullish-after-s-p-500-rises-for-fifth-consecutive-month"><em> Markets Remain Bullish After S&amp;P 500 Rises For Fifth Consecutive Month </em></a></p>


Pre-Market Outlook

Markets

Trading Ideas

Real Estate

Check Out 3 Real Estate Stocks With Over 6% Dividend Yields From Wall Street's Most Accurate Analysts

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments"><em> high dividend payout. </em></a></p>
<p>Benzinga readers can review the latest analyst takes on&nbsp;their favorite stocks&nbsp;by visiting our&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank">Analyst Stock Ratings&nbsp;</a>page. Traders can sort through Benzinga&#39;s extensive database of analyst ratings, including&nbsp;by analyst accuracy. Here&#39;s a look at the most recent high-yield dividend&nbsp;stock ratings from the most accurate Wall Street analysts, according to Benzinga&#39;s&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock&nbsp;</a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Ratings</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.</p>
<h3><strong>SL Green Realty Corp.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slg#NYSE">SLG</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 10.20%</li>
<li><strong>BMO Capital</strong> analyst John Kim upgraded the stock from Market Perform to Outperform with a price target of $30 on April 3, 2023. This analyst has an accuracy rate of 67%.</li>
<li><strong>Morgan Stanley</strong> analyst Ronald Josey maintained an Equal-Weight rating and cut the price target from $35 to $21 on March 31, 2023. This analyst has an accuracy rate of 70%.</li>
<li><strong>Recent News:</strong> SL Green Realty recently sold its 49.9% stake in the 245 Park Avenue property at a $2 billion valuation.</li>
</ul>
<h3><strong>Sabra Health Care REIT, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbra#NASDAQ">SBRA</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 9.46%</li>
<li><strong>Citigroup</strong> analyst Nicholas Joseph maintained a Neutral rating and raised the price target from $11 to $12.5 on July 14, 2023. This analyst has an accuracy rate of 63%.</li>
<li><strong>Credit Suisse</strong> analyst Omotayo Okusanya reiterated a Neutral rating with a price target of $13 on April 12, 2023. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News:</strong> Sabra Health Care REIT posted better-than-expected quarterly sales.</li>
</ul>
<h3><strong>Global Medical REIT Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gmre#NYSE">GMRE</a>)</h3>
<ul>
<li><strong>Dividend Yield:</strong> 8.55%</li>
<li><strong>B. Riley Securities</strong> analyst Bryan Maher maintained a Buy rating and cut the price target from $12 to $11 on May 8, 2023. This analyst has an accuracy rate of 66%.</li>
<li><strong>BMO Capital</strong> analyst John Kim downgraded the stock from Outperform to Market Perform and cut the price target from $13 to $9 on Oct. 6, 2022. This analyst has an accuracy rate of 67%.</li>
<li><strong>Recent News:</strong> Global Medical REIT posted downbeat first-quarter sales.</li>
</ul>
<p>&nbsp;</p>
<p>Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/07/33246725/top-5-tech-and-telecom-stocks-that-may-implode-this-quarter"><em> Top 5 Tech And Telecom Stocks That May Implode This Quarter </em></a></p>


SBRA

Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street's Most Accurate Analysts

<p>At the end of July 11, 2023, <strong>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>)</strong> will reward its shareholders with a dividend payout of $0.21 per share, demonstrating an annualized dividend yield of 9.08%. Remember, only investors who held the stock before the ex-dividend date on June 22, 2023 will receive this payout.</p>
<h3>Global Medical REIT Recent Dividend Payouts</h3>
<table>
<thead>
<tr>
<th><strong>Ex-Date</strong></th>
<th align="right"><strong>Payments per year</strong></th>
<th><strong>Dividend</strong></th>
<th><strong>Yield</strong></th>
<th><strong>Announced</strong></th>
<th><strong>Record</strong></th>
<th><strong>Payable</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2023-06-22</td>
<td align="right">4</td>
<td>$0.21</td>
<td>9.08%</td>
<td>2023-06-09</td>
<td>2023-06-23</td>
<td>2023-07-11</td>
</tr>
<tr>
<td>2023-03-23</td>
<td align="right">4</td>
<td>$0.21</td>
<td>8.7%</td>
<td>2023-03-10</td>
<td>2023-03-24</td>
<td>2023-04-11</td>
</tr>
<tr>
<td>2022-12-21</td>
<td align="right">4</td>
<td>$0.21</td>
<td>8.55%</td>
<td>2022-12-07</td>
<td>2022-12-22</td>
<td>2023-01-09</td>
</tr>
<tr>
<td>2022-09-22</td>
<td align="right">4</td>
<td>$0.21</td>
<td>7.8%</td>
<td>2022-09-09</td>
<td>2022-09-23</td>
<td>2022-10-11</td>
</tr>
<tr>
<td>2022-06-23</td>
<td align="right">4</td>
<td>$0.21</td>
<td>6.7%</td>
<td>2022-06-10</td>
<td>2022-06-24</td>
<td>2022-07-08</td>
</tr>
<tr>
<td>2022-03-24</td>
<td align="right">4</td>
<td>$0.21</td>
<td>5.41%</td>
<td>2022-03-11</td>
<td>2022-03-25</td>
<td>2022-04-08</td>
</tr>
<tr>
<td>2021-12-23</td>
<td align="right">4</td>
<td>$0.2</td>
<td>4.9%</td>
<td>2021-12-10</td>
<td>2021-12-27</td>
<td>2022-01-10</td>
</tr>
<tr>
<td>2021-09-23</td>
<td align="right">4</td>
<td>$0.2</td>
<td>5.24%</td>
<td>2021-09-10</td>
<td>2021-09-24</td>
<td>2021-10-08</td>
</tr>
<tr>
<td>2021-06-23</td>
<td align="right">4</td>
<td>$0.2</td>
<td>5.2%</td>
<td>2021-06-10</td>
<td>2021-06-24</td>
<td>2021-07-08</td>
</tr>
<tr>
<td>2021-03-23</td>
<td align="right">4</td>
<td>$0.2</td>
<td>6.07%</td>
<td>2021-03-02</td>
<td>2021-03-24</td>
<td>2021-04-08</td>
</tr>
<tr>
<td>2020-12-24</td>
<td align="right">4</td>
<td>$0.2</td>
<td>5.49%</td>
<td>2020-12-16</td>
<td>2020-12-28</td>
<td>2021-01-11</td>
</tr>
<tr>
<td>2020-09-23</td>
<td align="right">4</td>
<td>$0.2</td>
<td>5.97%</td>
<td>2020-09-03</td>
<td>2020-09-24</td>
<td>2020-10-08</td>
</tr>
</tbody>
</table>
<h3>Analyzing Global Medical REIT Financial Health</h3>
<p>Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing.</p>
<h3>YoY Growth in Dividend Per Share</h3>
<p><img alt="dividend chart graph" src="https://www.benzinga.com/files/images/story/2023/1689087920_0.png" /></p>
<p>Investors witnessed an upward trajectory in the company&#39;s dividend per share between 2019 and 2022. The dividend per share rose from $0.80 to $0.84, indicating the company&#39;s dedication to enhancing shareholder value through increased dividends.</p>
<h3>YoY Earnings Growth For Global Medical REIT</h3>
<p><img alt="earning chart graph" src="https://www.benzinga.com/files/images/story/2023/1689087920_1.png" /></p>
<p>The earnings chart illustrates an increase in Global Medical REIT&#39;s earnings per share, from $0.74 in 2019 to $0.98 in 2022. This positive earnings growth provides income-seeking investors with optimism, as it suggests potential for higher cash dividend payouts in the future.</p>
<h3>Recap</h3>
<p>This article takes an in-depth look at Global Medical REIT&#39;s recent dividend payout and its implications for shareholders. The company is currently distributing a dividend of $0.21 per share today, translating to an annualized dividend yield of 9.08%.</p>
<p>Considering the increase in dividend per share from 2019 to 2022 along with an increase in earnings per share, Global Medical REIT appears to be in a strong financial position, indicating their ability to sustain dividend distributions to investors.</p>
<p>It is advisable for investors to monitor the company&#39;s performance in the coming quarters to stay in the loop about any adjustments in financials or dividend disbursements.</p>
<p><em>This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.</em></p>


Exceeding Expectations: Global Medical REIT Achieves Strong Performance and Rewards Investors

<p>B. Riley Securities  analyst Bryan Maher   maintains Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy and lowers the price target from $12 to $11.</p>


B. Riley Securities Maintains Buy on Global Medical REIT, Lowers Price Target to $11

<p>Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share. This is a 4.17 percent decrease over earnings of $0.24 per share from the same period last year.  The company reported quarterly sales of $36.23 million which missed the analyst consensus estimate of $36.61 million by 1.04 percent.  This is a 13.66 percent increase over sales of $31.88 million the same period last year.</p>


Global Medical REIT Q1 FFO $0.23 Down From $0.24 YoY, Sales $36.23M Miss $36.61M Estimate

Mousetraps And Hot Potatoes:  2024 Performance Review

2025 Analyst Outlook: Brad Thomas On REIT Sector Opportunities And Market Conditions

KBWY: The 8.80% Dividend Yield May Start Growing Again In 2025

Dividend Cut Alert: 1 REIT And 1 BDC With Unsustainable Yields

In a report released yesterday, Kai Klose from Berenberg Bank maintained a Buy rating on Global Medical REIT (GMRE – Research Report), with a price...

Global Medical REIT (GMRE) Receives a Buy from Berenberg Bank

Global Medical REIT (GMRE) announced that as part of the company's succession planning efforts, the Board of Directors has reached an agreement wit...

Global Medical REIT says CEO transition expected in 2025

Global Medical REIT announces CEO succession plan

The latest announcement is out from Global Medical REIT ( ($GMRE) ). Global Medical REIT announced the transition of Jeffrey Busch from his role as...

Comments

Global Medical REIT

뉴스

에 대한 최신 뉴스 Global Medical REIT (NYSE:GMRE) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌